Longevity Research News: 12 Biggest Anti-Aging Breakthroughs (2025–2026)

1. First Human Trial of Epigenetic Reprogramming Gets FDA Clearance

In 2026, Life Biosciences received Investigational New Drug (IND) clearance from the FDA to test ER-100, an epigenetic reprogramming therapy, in patients with optic neuropathies. This makes it the first human trial of a cellular reprogramming technology, ever.

The therapy uses three of the four Yamanaka factors (Oct4, Sox2, and Klf4, known as OSK) delivered locally to the eye through a doxycycline-inducible system. The fourth factor, c-Myc, was deliberately excluded because of its well-documented association with uncontrolled cell growth and tumor formation. The inducible system is a critical safety feature: clinicians can switch the gene expression on and off with a common antibiotic, providing a braking mechanism that earlier reprogramming approaches lacked entirely.

The science behind this moment stretches back to 2006, when Shinya Yamanaka demonstrated that four transcription factors could reprogram adult cells back to an embryonic-like state. A discovery that earned the Nobel Prize in 2012. But full reprogramming erases cell identity. A heart cell stops being a heart cell. That is useful for generating stem cells in a lab, and dangerous inside a living body.

The critical conceptual leap from full reprogramming to partial reprogramming took another decade. Juan Carlos Izpisua Belmonte’s lab at the Salk Institute, and later at Altos Labs, showed that cyclic, transient expression of these factors in mice could extend lifespan, improve muscle regeneration, enhance pancreatic function, and restore youthful epigenetic profiles without triggering cancer. The key word is “cyclic”: short bursts of reprogramming followed by recovery periods, never long enough for cells to lose their identity.

Life Biosciences, founded on Harvard professor David Sinclair’s research, chose the eye as the target organ for a reason beyond biology. The eye is a relatively contained, immunologically privileged environment where a local injection limits systemic exposure. If something goes wrong, the consequences are more manageable than in a systemic therapy. Multiple preclinical animal models demonstrated controlled gene expression, favorable biodistribution, restoration of epigenetic markers, and improvements in visual function. Collectively providing the foundation for FDA clearance.

The competitive field is intense. Altos Labs (backed by $3 billion, including from Jeff Bezos) is pursuing partial reprogramming across multiple tissue types. Retro Biosciences (funded by OpenAI’s Sam Altman) is working on related approaches. NewLimit (co-founded by Coinbase’s Brian Armstrong) focuses on epigenetic reprogramming in the immune system. None of these have reached human trials yet. Life Biosciences got there first.

Why it matters for the broader field: If ER-100 demonstrates safety and efficacy in the eye, it establishes a regulatory precedent for reprogramming therapies in other tissues. More importantly, it proves that the concept works in humans, not just in mice. That would shift the entire field from “theoretically possible” to “clinically real.”

What you can do now: Nothing directly. Partial reprogramming is years away from clinical availability, and the current trial targets a specific eye condition, not aging broadly. The closest accessible interventions that influence epigenetic markers are lifestyle-based: caloric restriction, regular exercise, and adequate sleep have all been shown to slow epigenetic aging clocks in human studies. Among supplements, NAD+ precursors like NMN have been classified as potential epigenetic modulators within the 12 hallmarks of aging framework: NAD+ feeds into sirtuin activity, which directly regulates chromatin remodeling and DNA methylation patterns. The human evidence for this specific mechanism remains preliminary, though the biochemical pathway is well-established.

2. NMN and NR Double NAD+ Levels in Head-to-Head Human Trial

In January 2026, Cuenoud and colleagues from Nestlé Health Science published a landmark study in Nature Metabolism that directly compared three NAD+ precursors in 65 healthy adults for the first time. The study was randomized, placebo-controlled, and open-label with four arms: NMN, NR, nicotinamide (NAM), and placebo, each at 1,000 mg/day for 14 days.

The headline results: both NMN and NR approximately doubled whole-blood NAD+ concentrations after 14 days. The two precursors performed comparably. There was no statistically significant difference between them. Nicotinamide, the third precursor, only raised NAD+ acutely at four hours after supplementation and failed to sustain the increase over two weeks. NAM also increased homocysteine levels, reflecting increased methylation demand. A potential concern for long-term use.

Two secondary findings made this study more consequential than a simple precursor comparison. First, the researchers found evidence that gut bacteria convert both NMN and NR into nicotinic acid (NA), and that this microbial conversion is a meaningful contributor to the sustained NAD+ increase. This was not just a pharmacokinetic curiosity: it suggests that individual gut microbiome composition might explain why some people respond more strongly to NAD+ supplementation than others, a question that had been nagging researchers for years.

Second, both NMN and NR modulated gut bacteria composition in ways that increased short-chain fatty acid (SCFA) production. Specifically butyrate and propionate. SCFAs are metabolites associated with reduced systemic inflammation, improved gut barrier integrity, and even neuroprotective effects. If NAD+ precursors improve gut health as a secondary mechanism, the potential benefits extend beyond the NAD+ pathway itself.

Where the evidence stands overall: The 2026 Nature Metabolism trial did not exist in isolation. A meta-analysis by Zhang and colleagues, published in Critical Reviews in Food Science and Nutrition the same year, pooled 12 randomized controlled trials encompassing 513 participants. The aggregate finding: NMN supplementation reliably and significantly elevates NAD+ concentrations. That signal is now beyond dispute.

But the same meta-analysis delivered a sobering companion finding: NMN produced no statistically significant improvements in fasting glucose, insulin sensitivity, HbA1c, or lipid markers compared to placebo. A parallel meta-analysis by Chen and colleagues in Current Diabetes Reports (8 RCTs, 342 participants) reached the same conclusion from a slightly different pool of studies.

There is a genuine disconnect between the biochemical signal (NAD+ goes up) and the clinical outcome signal (metabolic markers do not clearly improve). Several explanations are plausible. Most trials enrolled relatively healthy adults in whom metabolic markers are already normal, leaving little room for improvement. Trial durations were short, typically 4 to 12 weeks, which may be insufficient for downstream functional effects to manifest. And the specific endpoints chosen (glucose, lipids) may not be the most sensitive markers for what NAD+ restoration actually does.

The Morifuji 2024 trial offered a counterpoint: 60 older adults taking just 250 mg NMN daily for 12 weeks showed significantly faster four-meter walking time versus placebo (p<0.05), elevated NAD+ levels (p<0.05), and improved sleep quality on the Pittsburgh Sleep Quality Index daytime dysfunction subscale (p<0.05). Physical function and sleep are rarely primary endpoints in NMN trials, which makes this finding notable. And it suggests the field may have been measuring the wrong things.

What you can do now: If your goal is NAD+ restoration, NMN and NR are both proven to double circulating NAD+ at 1,000 mg/day. For most people, 250–500 mg daily is a reasonable starting dose (see our NAD+ supplement guide comparing NMN, NR, and niacin). Morning dosing with food is the default recommendation; one trial (Kim 2022) found afternoon intake improved sleep quality and lower-limb function in older adults. YourHealthier offers a 500 mg NMN capsule with third-party COA testing for purity, heavy metals, and microbial contamination. See our complete NMN guide for dosage, timing, and what the research actually supports.

3. Senolytics Show Promise in Alzheimer’s — But Disappoint in Bone Health

Senolytic drugs. Compounds that selectively kill senescent “zombie” cells accumulating with age. Had a complicated 2024–2026. The results split sharply between encouraging signals in neurodegeneration and underwhelming outcomes in other conditions, painting a picture of a field that is further from clinical application than the hype suggests, but closer to breakthroughs in specific disease contexts than skeptics assumed.

The positive signal. Alzheimer’s disease: Two open-label Phase 1 trials tested intermittent dasatinib plus quercetin (D+Q) in older adults with Alzheimer’s disease or mild cognitive impairment.

SToMP-AD enrolled 5 participants with symptomatic AD (mean age 72, 60% female). After 12 weeks of intermittent D+Q, dasatinib was detected in cerebrospinal fluid in 80% of participants at concentrations of 0.281–0.536 ng/mL. This was the first confirmation that dasatinib reaches the brain at detectable levels, a fundamental prerequisite for any CNS-targeted senolytic. Quercetin was not detected in CSF, suggesting it may contribute through peripheral mechanisms rather than direct brain exposure. Plasma inflammatory markers, including SASP factors, decreased after treatment. CSF levels of IL-6 and GFAP increased, while the CTRA gene expression profile (a marker of systemic immune stress) decreased in four of five participants.

STAMINA enrolled 12 older adults with mild cognitive impairment and slow gait speed (mean age 77, 58% female). The headline finding: reductions in plasma TNF-α correlated significantly with improvements in Montreal Cognitive Assessment scores (r = −0.65, p = 0.02). When an inflammatory biomarker goes down and cognition goes up in a correlated fashion, it is at minimum a signal worth chasing in larger trials.

Both studies were small and uncontrolled. They cannot prove efficacy. But they demonstrated safety, feasibility, and biological plausibility in the brain. The three things a Phase 1 trial needs to accomplish to justify a Phase 2.

The disappointment. Bone health: A Phase 2 randomized controlled trial at Mayo Clinic tested D+Q in 60 postmenopausal women ages 62–88 over 20 weeks. Published in Nature Medicine in 2024, this was a properly powered, well-designed study. The result: only limited benefits in bone metabolism compared to the control group. The National Institute on Aging’s summary was blunt: senolytic therapy showed “just a subtle effect despite earlier promising evidence from mouse studies.”

This matters because the mouse-to-human translation gap is the central challenge of senolytic development. Mice accumulate senescent cells faster, have shorter lifespans for interventions to affect, and clear senescent cells more efficiently in response to senolytics. The bone trial suggests that at least for some tissues and conditions, the dramatic effects seen in mice may not translate proportionally to humans.

Unity Biotechnology’s collapse: The other major senolytic story was a failure. Unity Biotechnology’s lead candidate UBX1325, a BCL-xL inhibitor targeting senescent cells in the eye, failed its primary endpoint in a Phase 2 trial for wet age-related macular degeneration in 2023. The drug did not achieve non-inferiority to Regeneron’s Eylea. In March 2025, UBX1325 failed again in diabetic macular edema. Unity’s stock price collapsed, and the company restructured its pipeline.

What this means for you: Senolytics are not ready for general anti-aging use. The Alzheimer’s signals are notable but preliminary. The bone trial was properly controlled and showed marginal effects. Quercetin is available over the counter and has a strong safety profile, but quercetin alone is not a senolytic, the combination with dasatinib is what the research tests, and dasatinib is a chemotherapy drug with meaningful side effects. Fisetin, a flavonoid with senolytic properties in preclinical models, is being studied in human trials, but published clinical data is limited. For now, the most evidence-based way to reduce senescent cell burden is exercise: particularly high-intensity interval training, which has been shown to reduce markers of cellular senescence in human muscle tissue.

4. TAME Trial: Metformin as the First FDA-Recognized Aging Drug?

The Targeting Aging with Metformin (TAME) trial remains the most important clinical trial in geroscience. Not because metformin is necessarily the best longevity compound. Rapamycin has stronger preclinical data, and NAD+ precursors have more strong human supplementation data. TAME matters because it is the first trial designed to test a drug specifically for aging as an indication, with FDA recognition of the trial design.

As of mid-2026, the trial is still underway. Recruitment has been strong, with thousands of participants screened and enrolled across multiple sites. The trial targets adults 65–79 with at least one but not more than three age-related conditions. The primary endpoint is a composite of time to a new age-related chronic disease (cardiovascular disease, cancer, dementia, or mortality). Secondary endpoints include biomarkers of aging, functional measures, and quality of life.

Early biomarker analyses, while not yet published in full, suggest metformin influences inflammatory cytokines and metabolic markers. But early biomarker signals are not clinical endpoints, and the field has been burned before by interventions that moved biomarkers without moving outcomes.

Metformin works primarily through AMPK activation and mTOR inhibition, two of the same nutrient-sensing pathways that caloric restriction targets. It reduces hepatic glucose production, improves insulin sensitivity, and appears to reduce systemic inflammation through mechanisms that are not fully mapped. Observational data from the UK Clinical Practice Research Datalink showed that diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls. A striking finding, since diabetes itself is a disease of accelerated aging. But observational data is riddled with confounders. That is precisely why TAME exists.

Why TAME matters beyond metformin: The FDA does not currently recognize aging as a treatable condition. There is no ICD code for aging. This means no drug can be approved “for aging.” TAME is designed to change that framework. If the trial demonstrates that metformin delays multiple age-related diseases simultaneously, rather than treating one disease at a time, it establishes a regulatory precedent that aging itself is a modifiable upstream cause. That would open the door for other geroprotective compounds, rapamycin, senolytics, NAD+ precursors, and eventually reprogramming therapies. To pursue aging-specific indications.

What you can do now: Metformin requires a prescription. Side effects include gastrointestinal distress (particularly diarrhea and nausea during the first weeks), potential vitamin B12 depletion with long-term use, and in rare cases, lactic acidosis. Off-label use for longevity is increasingly common among longevity-focused physicians, but it is not evidence-based until TAME reports results.

Berberine, an over-the-counter plant alkaloid, activates AMPK through a mechanism that overlaps with metformin’s. Some researchers and biohackers position it as a metformin alternative. Head-to-head human data comparing the two specifically for aging outcomes does not exist. What does exist are diabetic trials showing berberine reduces fasting glucose and HbA1c comparably to metformin, though with a different side effect profile.

5. Rapamycin PEARL Trial: One-Year Human Safety Data

Rapamycin (sirolimus) remains the single most reliable lifespan extender across species. It has extended lifespan in yeast, worms, flies, and mice. Including in genetically diverse mouse populations and even when started late in life. No other compound has demonstrated that breadth of cross-species evidence.

The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial, the longest human rapamycin study for healthy aging to date, published its 48-week results in Aging in 2025. This decentralized, double-blinded, placebo-controlled trial tested 5 mg and 10 mg weekly compounded rapamycin against placebo in adults aged 50–85. The primary endpoint, visceral adiposity, did not change significantly. But women taking 10 mg weekly showed significant improvements in lean tissue mass (roughly 5% at 48 weeks) and self-reported pain. Critically, adverse events and serious adverse events were similar across all groups, and blood biomarkers stayed within normal ranges. Addressing the central safety question about whether low-dose intermittent rapamycin avoids the immune suppression seen at transplant doses.

This matters because rapamycin’s anti-aging potential has been debated for over a decade, largely because of its known side effects as an immunosuppressant at transplant doses. The PEARL trial tests whether low, intermittent dosing preserves the geroprotective benefits while minimizing immune suppression. A dose-dependent question that mouse studies could not answer definitively.

Separately, the Dog Aging Project’s TRIAD study received a $7 million grant to continue its rapamycin arm. Over 180 dogs have been enrolled toward a target of 580, with once-weekly weight-adjusted dosing. The primary endpoint is lifespan extension; secondary endpoints include physiological health and age-related disease markers. If rapamycin extends lifespan in a genetically diverse mammal that shares our living environment, diet, and many disease processes, it would be the strongest translational evidence any longevity compound has ever generated.

What you can do now: Rapamycin is a prescription immunosuppressant with real side effects at higher doses: impaired wound healing, mouth sores (aphthous ulcers), metabolic disruption (increased triglycerides, insulin resistance), and infection susceptibility. Low-dose, intermittent protocols (typically 3–6 mg once weekly) are used off-label by longevity physicians, but long-term safety data at these doses in healthy adults is exactly what PEARL is designed to generate. Self-medicating with rapamycin carries genuine risks that OTC supplements do not.

6. First Longevity Drug Approaching FDA Approval — for Dogs

Loyal’s LOY-002, a daily oral tablet designed to extend lifespan in senior dogs, cleared the FDA’s Reasonable Expectation of Effectiveness (RXE) standard in 2025 and is targeting conditional approval in 2026. If approved, it would be the first FDA-approved longevity drug for any species, a milestone whose implications extend well beyond veterinary medicine.

LOY-002 is formulated as a beef-flavored daily tablet for dogs 10 years and older, weighing at least 14 pounds. Essentially the entire senior dog population beyond the smallest toy breeds. The drug targets IGF-1 (insulin-like growth factor 1) signaling, the same pathway that explains one of the most consistent observations in aging biology: small dog breeds, which produce less IGF-1, outlive large breeds by 3–5 years on average. Safety data from over 400 dogs showed no clinically significant adverse events, even at five times the intended dose.

Loyal’s parallel product, LOY-001, targets large and giant breeds specifically through an injectable IGF-1 modulator administered every three to six months. Both products are supported by the STAY study, a large-scale, placebo-controlled clinical trial in senior dogs with 1,300 enrollees across the country.

In February 2026, Loyal announced a $100 million Series C funding round led by age13, with participation from Baillie Gifford, bringing total investment to over $250 million. That level of capital reflects institutional confidence that at least one of these drugs will reach market.

Why a dog drug matters for human longevity: Dogs age faster than humans but share our environment, circadian rhythms, diet patterns, emotional stress, and many disease processes including cancer, heart disease, and cognitive decline. A drug that extends healthy lifespan in dogs with a clean safety profile would dramatically strengthen the case for human translation: and provide the first proof of concept that pharmacological lifespan extension is achievable in a large, genetically diverse mammal.

7. GLP-1 Agonists Reveal Unexpected Anti-Aging Effects

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were developed for type 2 diabetes and obesity. But accumulating data from 2024–2026 has positioned these GLP-1 receptor agonists as the most impactful metabolic drugs in a generation: and the longevity implications are becoming difficult to ignore. For the weight-loss trial data, see our GLP-1 weight loss guide.

The SELECT trial (semaglutide in adults with overweight/obesity and cardiovascular disease) showed a 20% reduction in major adverse cardiovascular events, heart attack, stroke, and cardiovascular death, independent of diabetes status. The FLOW trial demonstrated significant kidney protection. Subsequent analyses showed reduced heart failure hospitalizations. These are not marginal effects. A 20% reduction in cardiovascular events rivals statins, and these benefits appear to extend beyond what weight loss alone would predict.

Researchers are now investigating whether GLP-1 agonists affect underlying aging biology, including chronic inflammation (a hallmark of aging), cellular senescence, and metabolic resilience. Metabolic syndrome. The cluster of insulin resistance, visceral obesity, hypertension, and dyslipidemia: is itself considered a driver of accelerated biological aging. A drug that resolves metabolic syndrome may be indirectly geroprotective even if it was never designed for that purpose.

What this means for longevity science: GLP-1 agonists may be the first widely prescribed medications that meaningfully reduce multiple age-related disease risks simultaneously. Whether they actually slow biological aging (as measured by epigenetic clocks or other biomarkers) or simply treat the diseases of aging more effectively than previous drugs is an open question that multiple research groups are actively studying.

What you can do now: GLP-1 agonists are prescription medications with significant side effects (nausea, gastroparesis risk, potential muscle mass loss) and high cost ($800–$1,500/month without insurance). They are FDA-approved for diabetes and obesity, not for longevity. The longevity community is watching whether ongoing studies show effects on biological aging clocks independent of weight loss.

8. Urolithin A Earns Strong Mitochondrial Health Data

Urolithin A (UA) stands out in the longevity supplement market for a specific reason: it has manufacturer-funded but properly designed, placebo-controlled clinical trials behind it. A rarity in a category where most products rely on preclinical data and mechanistic inference.

UA is a metabolite produced when gut bacteria process ellagitannins from pomegranates, walnuts, and berries. The catch is that only about 30–40% of people naturally produce meaningful amounts of UA from dietary sources, due to variation in gut microbiome composition. Supplementation bypasses this bottleneck.

The mechanism targets mitophagy. The selective clearance of damaged mitochondria. Mitochondrial dysfunction is one of the 12 hallmarks of aging, and the accumulation of dysfunctional mitochondria contributes to reduced cellular energy, increased oxidative stress, and tissue decline. A 2025 study demonstrated that UA supplementation preserved cardiac function in aging models by enhancing mitophagy efficiency. Earlier human trials showed UA improved muscle endurance and mitochondrial biomarkers (including a 60% increase in plasma acylcarnitines) in sedentary older adults over four months.

What you can do now: Urolithin A supplements are commercially available (Timeline’s Mitopure is the most studied brand). The evidence is promising for mitochondrial health specifically, though effects on lifespan or broad healthspan markers are not yet established. For mitochondrial support more broadly, NMN and CoQ10 target complementary pathways: NMN feeds NAD+ into mitochondrial energy production, while CoQ10 supports the electron transport chain directly. For a full breakdown of oral versus intravenous delivery, see our NAD+ IV therapy analysis.

9. AI Accelerates Longevity Drug Discovery

A 2025 study from Scripps Research Institute reported that AI-selected compounds achieved a greater than 70% success rate in extending lifespan in model organisms. The AI platform not only identified existing drugs with longevity potential but also designed novel compounds that outperformed their parent molecules. For context, the typical drug discovery success rate from early identification to clinical approval is under 10%.

This is not a single finding. It reflects a structural shift in how longevity research operates. Rubedo Life Sciences uses its ALEMBIC AI platform to identify druggable senescence targets and has moved its lead compound RLS-1496 into a Phase 1 trial. Gero, named a World Economic Forum Technology Pioneer, entered a collaboration with Chugai Pharmaceutical to use AI for age-related disease drug development, and raised $17 million in 2025 bringing total funding to $34 million. Insilico Medicine has advanced AI-discovered molecules into clinical trials for fibrosis. OpenAI partnered with a regenerative biology company in 2025 to engineer stem cell proteins using AI, the first biology-focused application of their technology, showing results that could improve stem cell production efficiency by up to 50 times.

Why this matters: The traditional drug discovery timeline: 10 to 15 years from target identification to approved therapy. Is incompatible with the urgency of the aging problem. AI compresses the early discovery phases from years to months by screening millions of molecular structures and predicting biological effects before any wet lab work begins. Whether AI-discovered compounds survive clinical trials at normal rates remains to be seen, but the pipeline acceleration is measurable and real.

10. Taurine Emerges as a Legitimate Longevity Molecule

A 2023 study published in Science, one of the highest-impact journals in all of biology, found that taurine levels decline substantially with age across mice, monkeys, and humans, and that taurine supplementation extended healthy lifespan in mice by 10–12% and in worms by a similar margin.

The study, led by Vijay Yadav at Columbia University, was notable for its scale, rigor, and breadth. It was not a single-organism experiment. The researchers demonstrated that taurine supplementation improved bone density, muscle endurance, insulin sensitivity, immune function, and reduced cellular senescence markers in mice. In monkeys, taurine reduced body weight, fasting blood glucose, and markers of liver damage. In humans, the correlational data showed that higher circulating taurine levels were associated with fewer metabolic risk factors. Though correlation is not causation.

By 2025–2026, taurine has entered the mainstream longevity supplement conversation alongside NMN, resveratrol, and berberine. The supplement industry is already marketing taurine for anti-aging, though human clinical trials specifically designed to test taurine for aging endpoints are still in early stages. The gap between the Science paper and clinical proof remains wide, but the preclinical evidence is among the strongest for any OTC compound, arguably comparable to what NMN had before its first human trials.

What you can do now: Taurine is inexpensive (typically $0.05–0.10 per gram), widely available, and has a long safety record from decades of use in energy drinks at 500–1,000 mg per serving. The mouse dose in the Yadav study translated to roughly 3–6 grams per day for humans based on standard allometric scaling. Human longevity data does not exist yet, but the tolerability profile at these doses is well-established.

11. Combination Therapy Becomes the Consensus Approach

One of the clearest intellectual shifts in 2025–2026 longevity science is the move away from single-target interventions toward combination strategies. This mirrors the trajectory of oncology, cardiology, and HIV treatment, where multi-drug regimens became standard decades ago: not because any single drug failed, but because the diseases themselves are multi-mechanism.

The logic is straightforward: aging involves at least 12 interconnected hallmarks. Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, and dysbiosis. Targeting only one, say, NAD+ decline with NMN, addresses a real mechanism but leaves the other 11 running. No single molecule is plausible as a complete anti-aging therapy.

The emerging clinical model combines interventions across multiple pathways:

NAD+ restoration (NMN or NR) targets mitochondrial function and DNA repair through sirtuin activation. mTOR inhibition (rapamycin or caloric restriction mimetics like berberine) addresses deregulated nutrient sensing. Senolytic clearance (D+Q, fisetin, or future targeted drugs) removes accumulated senescent cells. Metabolic optimization (metformin, GLP-1 agonists) improves insulin signaling and reduces chronic inflammation. Lifestyle foundations, exercise, sleep, and nutrition, remain the base layer, and the evidence for their efficacy exceeds that of any pharmaceutical intervention.

No large clinical trial has tested a combined longevity protocol against any single intervention. That study does not exist yet, and designing it is methodologically challenging: how do you isolate the contribution of each component when five interventions are running simultaneously? But the theoretical framework is now widely accepted across research groups from the Buck Institute to the National Institute on Aging to private longevity clinics. Several longevity physicians are already building patient protocols around multi-pathway targeting, tracking outcomes with biological age clocks and panel bloodwork. Our NMN supplement guide covers how to evaluate products for a stack like this.

What this means practically: For people building their own longevity strategy, the combination approach suggests prioritizing breadth over depth: hitting multiple aging pathways at moderate doses rather than maximizing a single intervention. A reasonable evidence-based stack might include NMN for NAD+ (250–500 mg/day), vitamin D3 for immune and bone health (2,000–5,000 IU/day), omega-3 for inflammation (2 g EPA+DHA/day), creatine for muscle and brain (3–5 g/day), and taurine for metabolic resilience (1–3 g/day), layered on top of consistent exercise, 7–8 hours of sleep, and a whole-food diet. See our full longevity supplements guide for the evidence behind each tier.

12. Biological Age Testing Goes Mainstream

Epigenetic clocks. Algorithms that estimate biological age from DNA methylation patterns: moved from niche research tools to consumer products in 2024–2026. Companies like TruDiagnostic, Elysium Health, and GlycanAge now offer tests priced between $200 and $500 that claim to measure how fast you are aging at a molecular level.

Steve Horvath’s GrimAge clock and Morgan Levine’s PhenoAge clock are the most validated in research settings. GrimAge has documented correlations to all-cause mortality, time to cancer, time to coronary heart disease, and composite health outcomes across multiple large cohorts. PhenoAge incorporates clinical biomarkers (albumin, creatinine, glucose, CRP, lymphocyte percentage) alongside methylation data.

The newer DunedinPACE clock, developed by a team at Duke University, measures the pace of aging rather than total biological age: essentially, how fast your clock is ticking right now. This makes it potentially more useful for tracking interventions: if you start NMN, exercise, or caloric restriction, DunedinPACE might detect a slowdown in weeks or months rather than requiring years of follow-up to see a shift in cumulative biological age.

The caveats are real: These tests measure biological signals that are truly correlated with health outcomes at a population level. But their clinical utility for individual decision-making remains debated. A single biological age measurement has limited actionability, it tells you where you are but not why, and the measurement-to-measurement variability is large enough that small changes might be noise rather than signal. Serial measurements over time, combined with functional tests (VO2 max, grip strength, cognitive assessments), are more informative than any single clock reading.

Biological age testing is best understood as one data point among many: a useful anchor for a longevity-oriented health strategy, not a definitive score. If you test, test repeatedly, and track trends rather than fixating on absolute numbers.

What Does This All Mean for You?

The longevity field in 2026 is defined by a gap. The science is further along than most people realize: multiple interventions have crossed from animal models into human trials, and several compounds reliably modulate known aging mechanisms in controlled studies. But the science is also less conclusive than supplement marketing suggests. No intervention has been proven to extend human lifespan in a controlled trial. None.

The honest framework for thinking about longevity interventions in 2026 looks like this:

Tier 1. Strong evidence, minimal risk: Exercise is the single most validated longevity intervention in humans, with decades of epidemiological and interventional data showing reduced risk of cardiovascular disease, cancer, dementia, and all-cause mortality. Sleep optimization (7–8 hours, consistent timing) reduces inflammatory markers and supports DNA repair processes. Mediterranean-pattern diets are associated with reduced biological aging in prospective cohort studies. Stress management through any effective modality (meditation, social connection, nature exposure) reduces cortisol-driven inflammation. These interventions are boring, free or cheap, and more effective than any pill currently available.

Tier 2, Promising evidence, established safety: NMN or NR for NAD+ restoration (see our best NMN supplements guide). Proven to double circulating NAD+ in humans at 1,000 mg/day within two weeks, with physical function improvements in some trials. Taurine. Strong preclinical evidence from a Science paper, long human safety record, low cost. Creatine monohydrate: cognitive and muscle preservation benefits in older adults across multiple meta-analyses. Vitamin D3. Deficiency correlates with accelerated biological aging and shorter telomere length. Omega-3 fatty acids: anti-inflammatory, with cardiovascular mortality reduction in large trials.

Tier 3. Interesting evidence, requires medical supervision: Rapamycin (prescription, real side effects, awaiting PEARL results). Metformin (prescription, awaiting TAME results). GLP-1 agonists (prescription, primarily for metabolic conditions, with emerging aging data).

Tier 4: Experimental, not yet actionable: Epigenetic reprogramming (first human trial just beginning). Senolytic therapies (small Phase 1 signals only). Gene therapies targeting aging pathways (preclinical stage).

The most rational approach in 2026 is to build Tier 1 into your daily life, consider Tier 2 based on your personal risk profile and health priorities, consult a physician before committing to anything in Tier 3, and wait for clinical data before counting on Tier 4.

The next two to three years will tell us more than the last two decades. TAME will report. PEARL will mature. The first reprogramming trial will generate safety data. And the NMN field will get its first 6-to-12-month outcomes trials. Watch this page, we update quarterly.

Sources

1. Christen S, Redeuil K, Goulet L, et al. "The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans." Nature Metabolism. 2026 Jan;8(1):62-73. PubMed · DOI
2. Zhang R, et al. Meta-analysis of NMN supplementation on NAD+ and metabolic outcomes (12 RCTs). Critical Reviews in Food Science and Nutrition. 2026. PubMed search
3. Prokopidis K, et al. "Effects of nicotinamide mononucleotide on muscle and metabolic outcomes in older adults: a meta-analysis." Journal of Cachexia, Sarcopenia and Muscle. 2025. PubMed
4. Katayoshi T, et al. "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial." Scientific Reports. 2023;13:2786. DOI
5. Yi L, Maier AB, Tao R, et al. "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults." GeroScience. 2023;45(1):29-43. PubMed
6. Fang EF, et al. "The first clinical trial of epigenetic reprogramming (ER-100): FDA IND clearance for optic neuropathies." Life Biosciences, 2026. Report
7. Ocampo A, Reddy P, Belmonte JCI, et al. "In vivo amelioration of age-associated hallmarks by partial reprogramming." Cell. 2016;167(7):1719-1733. PubMed
8. Farr JN, Atkinson EJ, Khosla S, et al. "Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial." Nature Medicine. 2024 Sep;30(9):2605-2612. DOI · NIH summary
9. Millar CL, Iloputaife I, Lipsitz LA, et al. "A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease (STAMINA)." eBioMedicine. 2025 Mar;113:105612. PubMed · DOI
10. Gonzales MM, Garbarino VR, Orr ME, et al. "Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (SToMP-AD)." Nature Medicine. 2023 Oct;29(10):2481-2488. PubMed · DOI
11. Singh P, Yadav VK, et al. "Taurine deficiency as a driver of aging." Science. 2023;380(6649):eabn9257. PubMed · DOI
12. Moel M, Harinath G, Lee V, et al. "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results." Aging (Albany NY). 2025 Apr 4;17(4):908-936. PubMed · DOI
13. Loyal (Cellular Longevity Inc.). "LOY-002 receives FDA Reasonable Expectation of Effectiveness (RXE) acceptance." December 2025. Company announcement
14. Barzilai N, et al. "Targeting Aging with Metformin (TAME): trial design and rationale." American Federation for Aging Research. 2025–2026. AFAR
15. Cheng FF, Liu YL, et al. "Metformin's mechanisms in attenuating hallmarks of aging and age-related disease." Aging and Disease. 2022;13(4):970-986. PubMed
16. Life Biosciences. "FDA clears first human trial of epigenetic reprogramming therapy (ER-100)." Longevity.Technology, 2026. Report

The longevity field moves fast. We update this article quarterly as new trial results and breakthrough studies are published. Last review: [Month] 2026.

Interested in NAD+ restoration? See our evidence-based guides: What Is NMN · NMN Before and After · NMN and Resveratrol · Longevity Supplements